|
Dr. Fruehauf is VP, Research at Cequent Pharmaceuticals, Inc. and co-inventor of transkingdom RNAi (tkRNAi). At Cequent, Dr. Fruehauf directs the research and development of novel therapeutics based on Cequent's proprietary technology. Prior to Cequent, Dr. Fruehauf was a group leader at the GI Cancer Laboratory at the Beth Israel Deaconess Medical Center, Harvard Medical School. Prior to his tenure at BIDMC, his clinical work focused on oncology, with an emphasis on breast cancer and gynecologic oncology, where he conducted clinical trials for neoadjuvant treatment of breast cancer at the University Hospital Mannheim. Dr. Fruehauf received his M.D. from the University of Frankfurt Medical School in 1997 and completed his doctoral thesis from the University of Heidelberg in 2000. | 